Medgenics, Inc. (NASDAQ: MDGN) today announced that the company has changed its name to Aevi Genomic Medicine, Inc. Aevi Genomic Medicine (pronounced "AHH-vee") is a name inspired by the Old Norse language which means "life story" and reflects the Company's mission of improving the lives of children and adults with pediatric onset life-altering diseases.

"The past year has been a period of transformational change for the company," said Michael F. Cola, President and Chief Executive Officer of Aevi Genomic Medicine. "The name change reflects the company's shift in strategy, our new business model and focus on genomic medicine."

In conjunction with the corporate name change, the company will trade on the NASDAQ Global Market under the new ticker symbol "GNMX". The new ticker will become effective at the open of the market on December 16, 2016. In addition, the company will have a new website address: www.aevigenomics.com.

About Aevi Genomic Medicine, Inc.

Aevi Genomics Medicine, Inc. is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the company's research and development efforts leverages an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP).